Trial · NCT00439244
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 | Zoledronic Acid Plus Teriparatide | 7.51 | Standard Error 0.414 | Percent change | |
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 | Zoledronic Acid | 4.37 | Standard Error 0.401 | Percent change | |
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52 | Placebo Zoledronic Acid Plus Teriparatide | 7.05 | Standard Error 0.398 | Percent change | |
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 13 and Week 26 | Zoledronic Acid Plus Teriparatide | At Week 13 (n= 127, 131, 131) | 4.65 | Standard Error 0.302 | Percent Change |
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 13 and Week 26 | Zoledronic Acid | At Week 13 (n= 127, 131, 131) | 2.97 | Standard Error 0.297 | Percent Change |
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 13 and Week 26 | Placebo Zoledronic Acid Plus Teriparatide | At Week 13 (n= 127, 131, 131) | 2.88 | Standard Error 0.297 | Percent Change |
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 13 and Week 26 | Zoledronic Acid Plus Teriparatide | At Week 26 (n= 128, 130, 132) | 6.31 | Standard Error 0.337 | Percent Change |
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 13 and Week 26 | Zoledronic Acid | At Week 26 (n= 128, 130, 132) | 3.87 | Standard Error 0.333 | Percent Change |
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 13 and Week 26 | Placebo Zoledronic Acid Plus Teriparatide | At Week 26 (n= 128, 130, 132) | 4.45 | Standard Error 0.330 | Percent Change |
| Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at Week 13, Week 26 and Week 52 | Zoledronic Acid Plus Teriparatide | At Week 13 (n= 127, 133, 133) | 2.54 | Standard Error 0.222 | Percent Change |
| Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at Week 13, Week 26 and Week 52 | Zoledronic Acid | At Week 13 (n= 127, 133, 133) | 1.53 | Standard Error 0.216 | Percent Change |
| Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at Week 13, Week 26 and Week 52 | Placebo Zoledronic Acid Plus Teriparatide | At Week 13 (n= 127, 133, 133) | 0.75 | Standard Error 0.216 | Percent Change |
| Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at Week 13, Week 26 and Week 52 | Zoledronic Acid Plus Teriparatide | At Week 26 (n= 128, 130, 133) | 2.31 | Standard Error 0.265 | Percent Change |
| Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at Week 13, Week 26 and Week 52 | Zoledronic Acid | At Week 26 (n= 128, 130, 133) | 1.73 | Standard Error 0.262 | Percent Change |
| Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at Week 13, Week 26 and Week 52 | Placebo Zoledronic Acid Plus Teriparatide | At Week 26 (n= 128, 130, 133) | 0.89 | Standard Error 0.259 | Percent Change |
| Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at Week 13, Week 26 and Week 52 | Zoledronic Acid Plus Teriparatide | At Week 52 (n= 123, 129, 129) | 2.33 | Standard Error 0.312 | Percent Change |
| Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at Week 13, Week 26 and Week 52 | Zoledronic Acid | At Week 52 (n= 123, 129, 129) | 2.16 | Standard Error 0.303 | Percent Change |
| Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at Week 13, Week 26 and Week 52 | Placebo Zoledronic Acid Plus Teriparatide | At Week 52 (n= 123, 129, 129) | 1.10 | Standard Error 0.304 | Percent Change |
| Bone Resorption and Formation Biochemical Markers : N-terminal Propeptide of Type I Collagen (P1NP) | Zoledronic Acid Plus Teriparatide | At Baseline (n= 126, 129, 121) | 52.72 | Standard Deviation 24.815 | ng/mL |
| Bone Resorption and Formation Biochemical Markers : N-terminal Propeptide of Type I Collagen (P1NP) | Zoledronic Acid | At Baseline (n= 126, 129, 121) | 53.64 | Standard Deviation 29.233 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00439244/results